Drugs / MEDI1191
last change Aug 2023 re-read 2 minutes ago

MEDI1191

Developed for
cancer
Investigated by
MedImmune LLC

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03946800 May 2019 → Aug 2023 cancer MedImmune LLC Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MEDI1191 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03946800